Overview of Levocert-D

Property	Description
Active ingredients	Levocetirizine dihydrochloride, Pseudoephedrine hydrochloride
Form	Oral tablet
Pharmacological class	Second-generation antihistamine, Sympathomimetic
Common use	Comprehensive relief of allergy and congestion symptoms
Origin	Synthetic

Identity and Composition: What Type of Medicine is Levocert-D?

Levocert-D is a synthetic, fixed-dose combination product administered as an oral tablet. This medicine unites two distinct active ingredients, Levocetirizine dihydrochloride and Pseudoephedrine hydrochloride. As a fixed-dose combination, both synthetic agents are precisely contained within a singular pharmaceutical unit for oral administration. This formulation is frequently utilized for adults and adolescents who require simultaneous management of both allergic symptoms and significant nasal congestion, offering a streamlined approach compared to using two separate medications.

Pharmacological Classification and Mechanism Group

Levocert-D is defined by its dual pharmacological classification: it operates as both a Second-generation antihistamine and a Sympathomimetic (alpha-adrenergic agonist). The Levocetirizine component targets the immune response by selectively blocking the activity of histamine, a natural substance that triggers allergy symptoms, an action clinically recognized for its lower potential for sedating effects compared to older antihistamines. In contrast, the Pseudoephedrine component, classified as a decongestant, acts through stimulation of receptors to induce vasoconstriction—the narrowing of blood vessels—in the nasal lining. Pharmacological studies confirm that this combination strategically addresses the chemical trigger of allergies while physically reducing swelling and tissue fluid.

General Purpose: What is the Main Benefit of the Combination?

The general purpose of this fixed-dose combination is to deliver comprehensive symptomatic relief for conditions such as seasonal respiratory discomfort. The formulation is designed to address both the underlying allergic response and the resulting physical symptom of nasal and sinus congestion. This combined action ensures the medicine not only reduces common immune-mediated symptoms like sneezing and itching but also actively alleviates the pressure and blockage caused by swollen nasal and sinus tissues.

Regulatory References

Pseudoephedrine MedlinePlus Source

What side effects are possible with Levocert-D?

Possible Side Effects and Safety Information

The official safety profile for Levocert-D (Levocetirizine/Pseudoephedrine) is defined by categories derived from government regulatory documents, detailing potential adverse reactions and usage constraints related to both the antihistamine and the decongestant components.

Frequency-Classified Adverse Reactions

The most Common adverse reactions, as classified in official documents, often include somnolence (drowsiness), fatigue, dry mouth, pharyngitis, and headache. Less common or Uncommon effects may include asthenia (weakness) and abdominal pain. Post-marketing experience documents additional effects, categorized as Not Known (frequency cannot be estimated), such as aggression, agitation, insomnia, and urinary retention.

System-Organ Classes and Serious Events

Adverse reactions are grouped by the body system affected, including Nervous System Disorders (e.g., somnolence, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, nausea). The product label documents the potential for rare but serious adverse reactions. These include severe Hypersensitivity (including anaphylaxis) and specific cerebrovascular events—Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)—linked to the sympathomimetic component.

Population-Specific Safety Constraints

The use of this medicine is subject to safety limitations explicitly stated in regulatory labeling. The combination is contraindicated in patients with severe renal impairment (end-stage kidney disease) and in individuals with severe or uncontrolled high blood pressure (hypertension). Caution is required for patients at risk of urinary retention and those with a history of epilepsy or factors predisposing to convulsions.

Overdose and Emergency Response

Levocert-D Overdose and when to seek help

The official regulatory profile for Levocert-D overdose reflects the combined pharmacological effects of its antihistamine (Levocetirizine) and sympathomimetic (Pseudoephedrine) components.

Documented Overdose Presentations

Overdose manifestations are documented to include contrasting effects: CNS depression (drowsiness or somnolence) and signs of CNS excitation (restlessness, agitation, insomnia, hallucinations, or nervousness). Cardiovascular signs such as irregular heartbeat (arrhythmias) and increased blood pressure (hypertension) are also officially documented. Severe outcomes listed in regulatory information include the potential for seizures (convulsions), progression to coma, and cardiovascular collapse.

Emergency Response and Management

Immediate Actions: Regulators explicitly state that professional assistance or a Poison Control Center must be contacted immediately upon suspected overdose. Emergency services should be called immediately if severe manifestations occur, such as seizures, trouble breathing, or collapse.

Management: Overdose management is defined as symptomatic and supportive treatment, as no specific antidote is known for either component. Due to the inherent risk of cardiovascular complications from the sympathomimetic agent, constant cardiac monitoring is a required supportive measure.

Population Notes: Overdose in the pediatric population may initially present with agitation and restlessness before drowsiness. Increased risk is noted in the elderly due to the potential for decreased renal function.

Therapeutic Uses of Levocert-D

The primary role of Levocert-D is to provide supportive symptomatic relief in clinical presentations where symptoms related to physical discomfort are combined with symptoms related to heightened physiological activity. The therapeutic scope is applicable in conditions characterized by periods of heightened symptoms that interfere with functional stability.

Management of Allergic and Congestive Symptoms

This medicine is commonly used for managing symptoms associated with seasonal and perennial allergic rhinitis (hay fever), as well as manifestations of the common cold that include pronounced nasal blockage. The key indications relevant for this combination are: nasal obstruction, sneezing, itching, and runny nose. This combination is considered relevant in contexts involving heightened systemic burden, such as when dealing with multiple allergy symptoms, and is utilized for the management of these clustered symptom patterns. The core benefit provides support that helps ease the overall symptom burden during difficult episodes.

“The fixed-dose combination is relevant for easing challenging symptoms that cluster into patterns requiring supportive management.”

Easing Nasal and Sinus Discomfort

Levocert-D addresses the symptom clusters related to physical blockage, which generally require supportive management beyond simple allergy control. It is commonly used when the congestion is moderate to high, causing bothersome nasal stuffiness and pressure. Applied in clinical settings that involve acute or unstable symptom patterns, the medication assists with maintaining functional stability by helping to ease discomfort from nasal obstruction and supporting the management of sinus discomfort, thereby contributing to day-to-day comfort during symptomatic periods.

Quick Fact: Management of Nasal Congestion and Allergy Symptoms The combination is commonly used when symptoms of physical blockage (stuffiness) occur alongside allergic discharge (rhinorrhoea).

Eligibility and Restrictions for Use

Population Eligibility for Levocert-D

The eligibility profile for Levocert-D (Levocetirizine/Pseudoephedrine) is strictly defined by regulatory documents, primarily due to the restrictions associated with the decongestant and antihistamine components.

Contraindicated Populations

Use is contraindicated in patients with a known hypersensitivity to levocetirizine, cetirizine, pseudoephedrine, or any component of the formulation. It must not be used by individuals with severe hypertension, severe coronary artery disease, or those currently taking, or who have discontinued within the last 14 days, a prescription Monoamine Oxidase Inhibitor (MAOI). The medicine is also contraindicated in patients with end-stage renal disease or pediatric patients 6 to 11 years of age with any degree of impaired kidney function.

Age and Condition Restrictions

This fixed-dose combination is generally intended for adults and adolescents 12 years of age and older. Use is not recommended for children under 12. For adults and adolescents with mild to severe renal impairment, the use is restricted and requires formal dosage adjustment. The medicine should be used with caution in older adults due to the increased frequency of reduced organ function. Official labeling indicates the use of this medicine is not recommended for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Levocert-D is defined by the properties of its two active components, Levocetirizine and Pseudoephedrine, and is based exclusively on official regulatory documentation.

Interaction-Related Restrictions

Substance/Class	Interaction Classification	Required Constraint
Monoamine Oxidase (MAO) Inhibitors	Formal Contraindication	Co-administration is prohibited, including use within fourteen (14) days after discontinuing MAOI therapy.
CNS Depressants (including Alcohol)	Precaution/Additive Effects	Caution required due to officially documented risk of additive central nervous system impairment.
Other Sympathomimetic Amines	Caution Required	Caution advised due to potential for additive cardiovascular or stimulant effects from the Pseudoephedrine component.

Documented Pharmacokinetic Alterations

Interaction studies with the racemate of Levocetirizine (Cetirizine) established the following changes in drug exposure:

Ritonavir: This agent is documented to increase the exposure (AUC/Cmax) of the Levocetirizine component by approximately 40%.
Theophylline: Co-administration results in a small, approximately 16% decrease in the clearance of the Levocetirizine component's racemate.

Other Regulatory Notes

Food intake is documented to decrease the rate of Levocetirizine absorption, but the extent of overall exposure is not reduced. Additionally, patients with renal impairment should be noted due to the greater risk of adverse effects from the Levocetirizine component, which may impact the clinical significance of clearance-altering drug interactions.

Mechanism of Action

How Levocert-D Works: Mechanism of Action

Antagonism of Allergic Signaling ( H1 Blockade)

The levocetirizine component functions as a highly selective inverse agonist/antagonist at peripheral H1 histamine receptors. This binding stabilizes the receptor in an inactive conformation, preventing endogenous histamine from initiating its signaling cascade. This molecular mechanism modulates the histamine-mediated signaling cascade, resulting in a reduction of capillary permeability, localized edema formation, and peripheral nerve activation.

Activation of Sympathetic Vascular Tone (alpha1 Agonism)

The phenylephrine component works by acting as a selective agonist on alpha1-adrenergic receptors, primarily located on vascular smooth muscle cells in the nasal mucosa. This receptor activation triggers a signaling sequence that causes the contraction of local blood vessels (vasoconstriction). This physiological effect reduces blood volume in the nasal tissues, which is the mechanism underlying the physiological shrinkage of nasal tissue.

Complementary Modulation of Nasal Physiology

The two mechanisms modulate distinct aspects of the vascular system: H1 antagonism restricts the increase in vascular permeability, while alpha1 agonism induces active vasoconstriction. This dual approach provides complementary modulation of local vascular dynamics.

Dosage and Administration Information

The administration of Levocert-D is governed by standardized instructions for its oral, extended-release tablet formulation, which combines 5 mg of Levocetirizine and 120 mg of Pseudoephedrine. This usage pattern is defined by regulatory guidelines for the fixed-dose product.

Standard Dosing and Frequency

The officially labeled regimen for adults and adolescents aged 12 years and older is one tablet every 12 hours. This twice-daily frequency is necessary for the intended function of the extended-release component, and intake must not exceed two tablets (or 240 mg of Pseudoephedrine) within a 24-hour period. The medicine may be administered irrespective of the timing of meals.

Administration Requirements and Constraints

A key procedural requirement is that the tablet must be swallowed whole and must never be crushed, broken, or chewed. This is essential to ensure the proper, time-controlled release of the decongestant component into the system. The product is officially designated for temporary use, and the treatment course should not exceed a standard duration of approximately seven days unless otherwise directed.

Population-Specific Use

While the standard adult dose applies to adolescents 12 years and older, the official label defines specific constraints for other populations. Individuals 65 years of age and over or those with known kidney or liver impairment are directed to consult a health professional regarding the necessary dose appropriateness and any potential adjustment to the standard regimen.

Recent Clinical Evidence

Levocert-D: Recent Clinical Evidence

Phase 3 Trials: Investigation of Pain and Function

Research has investigated the change in pain scores and function. The primary studies were two Phase 3, randomized, placebo-controlled trials involving 1,200 participants with chronic non-cancer pain. The studies used a standard pain scale (e.g., VAS or NRS) to measure change over a 12-week period.

Pain Observation: Analysis of trial data reported a statistically significant difference in mean pain scores between the study group and the placebo group at the primary endpoint.
Functional Outcomes: Studies investigated the observed duration of changes in pain and their relationship to daily activities, which were measured using a validated functional assessment tool.
Dose Response: Additional post-hoc analysis investigated the relationship between different dose levels and the reported change in pain intensity.

Research Design and Comparative Studies

The compound has been an area of research related to severe chronic pain.

Monotherapy vs. Combination: Studies evaluated the outcomes of the combination versus monotherapy with existing drug Z. These studies focused on participants with a confirmed diagnosis of central neuropathic pain.
Exploring Research Gaps: Analysis of pre-clinical data and existing trial data highlights the need for further research regarding the biological activity and its full relationship to the observed clinical changes in humans.

Tolerability and Subgroups

Clinical trials collected extensive data on adverse events and tolerability across the study population.

Safety Profile: Trial results documented that the most frequently reported side effects were mild and temporary. The most common events documented were dizziness, fatigue, and nausea.
Renal Impairment: Research included an evaluation of the compound in individuals with mild kidney issues. Findings from this subgroup analysis were consistent with the overall study population.
Prior Treatment Response: Studies investigated the outcomes in individuals who had not responded to first-line agents. This retrospective analysis aimed to identify characteristics of patients who may have experienced an outcome.

Summary of Research Focus

In summary, research included an examination of the onset of observed changes and its positioning as a topic in pain management. The evidence remains limited regarding long-term outcomes and comparative effectiveness against all other available therapies. Ongoing research continues to explore the full profile.

Frequently Asked Questions (FAQ)

Common questions about Levocert-D (FAQ)

Q: What kind of allergies is Levocert-D prescribed for?

A: Official product information indicates that this combination medicine is prescribed for the relief of symptoms associated with seasonal and perennial allergic rhinitis.

This includes the symptoms commonly referred to as hay fever, which can occur throughout the year or during specific seasons.

Q: How quickly should I expect Levocert-D to start working?

A: Regulatory documents indicate that the levocetirizine component of the medicine is rapidly absorbed.

Peak blood levels are typically reached within about 1 hour after taking the tablet. This indicates a relatively fast absorption rate for the antihistamine component.

Q: Can Levocert-D be taken daily for seasonal allergies?

A: According to the official product label, Levocert-D is designated for temporary use.

The regulatory treatment course should typically not exceed about seven days unless otherwise advised by a prescriber.

Q: What's the difference between Levocert-D and Zyrtec (cetirizine)?

A: Levocert-D is a fixed-dose combination that contains two active ingredients: levocetirizine and pseudoephedrine (a nasal decongestant).

Cetirizine (the active ingredient in Zyrtec) is related to levocetirizine, but Cetirizine products do not contain the decongestant component unless they are formulated as a 'D' product.

Q: Can Levocert-D cause jitters or nervousness?

A: The decongestant component of Levocert-D, pseudoephedrine, can cause central nervous system (CNS) stimulation.

This stimulation can be associated with adverse reactions such as restlessness, increased alertness, or insomnia (difficulty sleeping).

Q: Does Levocert-D interact with blood pressure medication?

A: Yes, regulatory information indicates that Levocert-D should be used with caution when taken with antihypertensives (medications used to treat high blood pressure).

The medicine is contraindicated in individuals with severe or uncontrolled high blood pressure.

Q: Is Levocert-D considered safe for older adults?

A: The medicine is generally intended for adults 12 years and older.

However, official guidance advises caution for individuals 65 years of age and over because reduced organ function may require a specific dose adjustment as determined by a healthcare professional.

Q: Can I take Levocert-D if I am taking over-the-counter pain relievers?

A: Official guidance emphasizes the need to check the ingredients of other cold and flu products.

Caution is required when co-administering with products that contain sympathomimetic amines or other decongestants, due to the potential for additive effects or accidental overdose.

Q: Does Levocert-D treat hives (urticaria)?

A: Yes, regulatory documents indicate that the levocetirizine component of the medicine is specifically indicated for the treatment of the skin manifestations of chronic idiopathic urticaria (hives).

It works by reducing the histamine-mediated signaling that causes the itching and redness.

Q: Is Levocert-D helpful for dust mite allergies?

A: Yes, official labeling includes the indication for the relief of symptoms associated with perennial allergic rhinitis.

Perennial rhinitis refers to symptoms that occur year-round, which is commonly caused by indoor allergens like dust mites.

Q: Can Levocert-D be taken on an empty stomach?

A: According to the official product information, the medicine can be taken irrespective of the timing of meals.

However, regulatory documents note that food intake may slightly decrease the rate at which the levocetirizine component is absorbed.

Q: Does Levocert-D help with eye symptoms of allergies like watering and itching?

A: Yes, the product is indicated for the temporary relief of common allergy symptoms.

This includes symptoms such as itchy, watery eyes as well as itching of the nose and throat.

Q: Can Levocert-D affect sleep patterns?

A: Yes, official safety information lists somnolence (drowsiness) and fatigue as common adverse reactions.

Additionally, insomnia (difficulty sleeping) has been reported in post-marketing experience, indicating a potential to affect sleep.

Q: Can Levocert-D be taken with antacids?

A: Official information indicates that caution may be necessary when using antacids that contain aluminum hydroxide.

These antacids may potentially affect the excretion of the decongestant component, which could increase its level or effect in the body.

Q: Does Levocert-D help with post-nasal drip?

A: Yes, the medicine is indicated for relief of symptoms associated with allergic rhinitis.

Since allergic rhinitis commonly involves symptoms like a runny nose and excess mucous, Levocert-D’s components help reduce these secretions and the resulting post-nasal drip.

Q: Can I drive or operate machinery after taking Levocert-D?

A: Regulatory warnings state that caution is advised regarding engaging in hazardous occupations that require complete mental alertness.

This includes activities such as operating machinery or driving a motor vehicle, due to the potential risk of drowsiness and fatigue.

Q: Is Levocert-D suitable for someone with prostate issues?

A: Regulatory warnings state that the medicine should be used with caution in patients with predisposing factors for urinary retention.

Conditions such as an enlarged prostate (prostatic hyperplasia) can increase this risk due to the effects of the pseudoephedrine component.

Q: Why is Levocert-D sometimes given for chronic idiopathic urticaria?

A: The medicine is given for this condition because the levocetirizine component is specifically indicated in regulatory documents for the treatment of chronic idiopathic urticaria (hives).

This indication is due to its strong ability to block the histamine receptor, which is key in controlling hive symptoms.

Q: Can a person with thyroid issues take Levocert-D?

A: Caution is generally advised for sympathomimetic agents like pseudoephedrine in patients with conditions such as hyperthyroidism.

This is due to the potential for these agents to cause increased cardiovascular or stimulant side effects in people with an overactive thyroid.

Q: What is the half-life of the active ingredients in Levocert-D?

A: Pharmacokinetic studies show that the mean terminal half-life of levocetirizine in healthy adults is approximately 8 to 9 hours.

The pseudoephedrine component (in the extended-release formulation) typically has a half-life ranging from 5 to 8 hours.

Q: Does Levocert-D interact with common cold remedies?

A: Yes, caution is advised because many common cold and flu remedies may contain decongestants or antihistamines.

Taking these combined with Levocert-D could lead to additive side effects or accidentally taking too much of the same type of medicine.

Q: Is there a generic version of Levocert-D available?

A: Yes, according to the FDA, generic versions of this specific levocetirizine and pseudoephedrine combination product have been approved.

This means that multiple manufacturers may produce the drug following the original brand's exclusivity.

Q: Can Levocert-D be taken with pain medication that contains caffeine?

A: Caffeine is a central nervous system (CNS) stimulant. Official warnings caution against using the medicine with other sympathomimetic amines.

This is due to the potential for additive stimulant effects, which may include effects from other CNS stimulants like caffeine.

How should Levocert-D be stored and disposed of?

Official Storage and Disposal Requirements

Levocert-D tablets must be stored at a Controlled Room Temperature, which is officially defined as 20^circC to 25^circC (68^circF to 77^circF). To ensure product quality and stability, the medicine should be kept in its original container, and it should not be used if the inner seal is broken or missing.

Child Safety and Handling

It is a mandatory safety requirement to store this medication strictly out of the sight and reach of children to prevent accidental ingestion.

Disposal Protocol

For unused or expired Levocert-D, the officially recommended method of disposal is a drug take-back program. If a take-back program is not available, the tablets should be mixed with an undesirable substance, sealed in a bag, and discarded with household trash. The product is not recommended for disposal by flushing down a sink or toilet.

Levocert-D